Scientists at The University of Manchester have developed the first non-antibiotic drug to successfully treat tuberculosis in animals.
The team hope the compound –developed after 10 years of painstaking research will be trialled on humans within three to four years.
The drug- which works by targeting Mycobacterium tuberculosis’ defences rather than the bacteria itself – can also take out its increasingly commonly antibiotic resistant strains.
The research funded by the Medical Research Council – is published today in the Journal of Medicinal Chemistry.
Although a vaccine for TB was developed 100 years ago, one in three people across the world are thought to be infected with the infectious disease.
About 1.7 million die from the bug each year worldwide and 7.3 million people were diagnosed and treated in 2018, up from the 6.3 million in 2016.
It is most common in Africa, India and China, but on the rise in the UK with London often described as the TB capital of Europe.
Patients are forced to take a cocktail of strong antibiotics over 6 to 8 months, often enduring unpleasant side effects with a 20% risk that the disease will return.
But now The University of Manchester team’s discovery has been proven effective in guinea pigs at Rutgers University in the United States.
The animals with acute and chronic TB infection were treated with the compound, which was discovered after investigating dozens of other derivatives and compounds thought to have similar properties.
Professor Lydia Tabernero is the project leader. She said: “The fact that the animal studies showed our compound, which doesn’t kill the bacteria directly, resulted in a significant reduction in the bacterial burden is remarkable.
“For more than 60 years, the only weapon doctors have been able to use against TB is antibiotics. But resistance is becoming an increasingly worrying problem and the prolonged treatment is difficult and distressing for patients.
“And with current treatments, there’s no guarantee the disease will be eliminated: antibiotics do not clear the infection and the risk of being infected with drug-resistant bacteria is very high.
“But by disabling this clandestine bacteria’s defences we’re thrilled to find a way that enhances the chances of the body’s immune system to do its job, and thus eliminate the pathogen.”
Mycobacterium Tuberculosis secretes molecules called Virulence Factors – the cell’s secret weapon -which block out the immune response to the infection, making it difficult to treat.
The team identified one Virulence Factor called MptpB as a suitable target, which when blocked allows white blood cells to kill Mycobacterium Tuberculosis in a more efficient way
Professor Tabernero added: “The great thing about MptpB is that there’s nothing similar in humans – so our compound which blocks it is not toxic to the human cells.
“Because the bacteria hasn’t been threatened directly, it is less likely to develop resistance against this new agent, and this will be a major advantage over current antibiotics, for which bacteria had already become resistant.
“TB is an amazingly difficult disease to treat so we feel this is a significant breakthrough.
”The next stage of our research is to optimise further the chemical compound, but we hope clinical trials are up to four years away.”
Learn more: Scientists develop new drug treatment for TB
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- 2018 Global Tuberculosis (TB) Testing Market - Supplier Shares & Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and ... on December 19, 2018 at 12:59 am
DUBLIN--(BUSINESS WIRE)--The "2018 Global Tuberculosis (TB) Testing Market: US, Europe, Japan - Supplier Shares and Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, ... […]
- Nearly one in five Tibetan refugee schoolchildren has tuberculosis infection, study finds on December 18, 2018 at 8:11 am
In a tuberculosis screening and treatment initiative covering the entire population of Tibetan refugee schoolchildren in northern India, a team directed by researchers at Johns Hopkins Medicine ... […]
- Nearly one in five Tibetan refugee schoolchildren has tuberculosis infection, Johns Hopkins study finds on December 18, 2018 at 7:43 am
In a tuberculosis screening and treatment initiative covering the entire population of Tibetan refugee schoolchildren in northern India, a team directed by researchers at Johns Hopkins Medicine and th... […]
- Tuberculosis Treatment market production: Regional Analysis for the United States, Europe, China, and Japan on December 13, 2018 at 11:55 pm
Global Tuberculosis Treatment Market Report is the latest offering at ‘The Market Reports’ which is in-depth analysis of the market and helps an individual or company to understand the market scenario ... […]
- Tuberculosis case spurs testing of students on December 13, 2018 at 6:34 pm
BUFFALO, NY (WIVB)- Nearly two hundred students in the Amherst area have been advised by the Erie County Department of Health to get tested for tuberculosis as they may have come in contact with a mem... […]
- Lung lavage as new test method improves tuberculosis diagnosis in rhinoceros on December 13, 2018 at 6:27 am
Scientists performed repeated lung lavage as a new approach for tuberculosis diagnosis in rhinoceros. Subsequent genetic tests reliably identified mycobacteria in the animals' respiratory fluids -- wi... […]
- GHIT Fund Announces New Investments in Vaccines for Dengue and Leishmaniasis, and Drug Screening for Malaria and Tuberculosis on December 12, 2018 at 5:08 pm
TOKYO, Dec. 12, 2018 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of 520 million yen (US$4.6 million*) to support four partnerships to develop new lifesa... […]
- Active tuberculosis case confirmed in individual who works in Williamsville schools on December 12, 2018 at 12:00 pm
(WIVB) - Erie County Health Commissioner Gale Burstein confirmed Wednesday during a press conference that an active case of tuberculosis has been confirmed in an individual who works with children in ... […]
- Schrödinger, TB Alliance collaborate to advance tuberculosis drug discovery on December 12, 2018 at 3:45 am
Schrödinger and TB Alliance have entered into a three-year research collaboration to enhance the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced comput... […]
via Bing News